Tuberculosis Diagnosis and Treatment Center, Tongji University School of Medicine, Shanghai, China.
Jpn J Infect Dis. 2011;64(6):509-12.
Linezolid is a new antibiotic with activity against Mycobacterium tuberculosis in vitro and in vivo. This study aims to evaluate the efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis (XDR-TB). We used a linezolid-containing regimen in the treatment of 14 XDR-TB patients. Two years of individualized chemotherapy regimens were adopted on the basis of the patients'medication history and the results of drug susceptibility testing. The patients received 600 mg of linezolid twice a day for the first 1-2 months, followed by once a day thereafter. Eleven patients (78.6%) showed significant improvement in clinical symptoms. Chest computed tomography revealed that 10 patients (71.4%) showed cavity closure. Smear conversion and culture conversion were achieved in all 14 patients (100%) with an average of 64 and 63 days, respectively. The exact proportions of serious and minor adverse events determined by linezolid were 21.4% (3/14) and 64.3% (9/14), respectively. These data show that linezolid-containing chemotherapy for the treatment of XDR-TB may significantly improve clinical symptoms, promote lesion absorption and cavity closure, and accelerate sputum conversion. Further, adverse reactions can be tolerated and resolved with suitable intervention.
利奈唑胺是一种新的抗生素，具有抗结核分枝杆菌的体外和体内活性。本研究旨在评估利奈唑胺治疗广泛耐药结核病（XDR-TB）的疗效和安全性。我们使用含利奈唑胺的方案治疗 14 例 XDR-TB 患者。根据患者的用药史和药敏试验结果，采用个体化化疗方案 2 年。患者在最初的 1-2 个月内每天接受 600 毫克利奈唑胺两次，之后每天一次。11 例（78.6%）患者的临床症状明显改善。胸部计算机断层扫描显示 10 例（71.4%）患者的空洞闭合。所有 14 例患者（100%）的涂片和培养均转为阴性，平均分别为 64 天和 63 天。利奈唑胺确定的严重和轻微不良事件的确切比例分别为 21.4%（3/14）和 64.3%（9/14）。这些数据表明，含利奈唑胺的化疗方案治疗 XDR-TB 可能显著改善临床症状，促进病变吸收和空洞闭合，并加速痰菌转化。此外，不良反应可以通过适当的干预得到耐受和解决。
